High-Intensity Functional Training vs. Moderate-Intensity Continuous Training in Cardiovascular Disease Patients
NCT07929701, Not applicable, Not yet recruiting, University of Miami
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | High-Intensity Functional Training vs. Moderate-Intensity Continuous Training in Cardiovascular Disease Patients | ClinicalTrials.gov |
| NCT number | NCT07929701 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 200 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Miami | ClinicalTrials.gov |
| Conditions | Cardiovascular Disease (CVD) | ClinicalTrials.gov |
| Interventions | High-Intensity Functional Training (HIFT), Moderate-Intensity Continuous Training (MICT) | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in Carotid-Femoral Pulse Wave Velocity (cfPWV) | Baseline and Week 12 (post-intervention) | Carotid-Femoral Pulse Wave Velocity (cfPWV) will be measured in meters per second (m/s) as an indicator of arterial stiffness. Measurement will be obtained using the SphygmoCor XCEL device (AtCor Medical) with upper arm and thigh cuffs with carotid artery applanation tonometry to assess pulse wave transit time. | ClinicalTrials.gov |
| Primary | Change in Central Augmentation Index (cAIx) | Baseline and Week 12 (post-intervention) | Central Augmentation Index (cAIx) expressed as a percentage (%) will be assessed using the SphygmoCor XCEL device via pulse wave analysis of the central arterial waveform derived from carotid artery tonometry and peripheral blood pressure measurements. | ClinicalTrials.gov |
| Primary | Change in Mean Arterial Pressure (MAP) | Baseline and Week 12 (post-intervention) | Mean Arterial Pressure (MAP) measured in millimeters of mercury (mmHg), will be estimated using the SphygmoCor XCEL device based on an algorithm derived from peripherally measured blood pressure obtained from an automated upper arm cuff. | ClinicalTrials.gov |
| Primary | Percent Change in Flow-Mediated Dilation (FMD) | Baseline and Week 12 (post-intervention) | Flow-Mediated Dilation (FMD) will be measured using a Philips Affiniti 50 ultrasound system. FMD will be expressed as percent (%) change in brachial artery diameter from pre-occlusion baseline to peak dilation following a 5-minute forearm occlusion. | ClinicalTrials.gov |
| Primary | Change in Carotid Intima-Media Thickness (cIMT) | Baseline and Week 12 (post-intervention) | Carotid Intima-Media Thickness (cIMT), measured in millimeters (mm), will be assessed using a Philips Affiniti 50 ultrasound system. High-resolution B-mode images of the distal common carotid artery will be acquired, and mean wall thickness will be calculated from standardized image segments of the left and right carotid arteries. | ClinicalTrials.gov |
| Secondary | Change in Body Mass Index (BMI) | Baseline and Week 12 (post-intervention) | Change in body mass index (BMI), measured in kilograms per square meter (kg/m²), will be calculated as weight in kilograms divided by height in meters squared. | ClinicalTrials.gov |
| Secondary | Change in Waist Circumference | Baseline and Week 12 (post-intervention) | Change in waist circumference, measured in centimeters (cm), will be assessed using a standardized measuring tape. | ClinicalTrials.gov |
| Secondary | Change in Body Fat Percentage | Baseline and Week 12 (post-intervention) | Change in body fat percentage, measured as a percentage (%), will be assessed using the SECA mBCA bioelectrical impedance analysis system. | ClinicalTrials.gov |
| Secondary | Change in Skeletal Muscle Mass | Baseline and Week 12 (post-intervention) | Change in skeletal muscle mass, measured in kilograms (kg), will be assessed using the SECA mBCA bioelectrical impedance analysis system. | ClinicalTrials.gov |
| Secondary | Change in Visceral Adipose Tissue | Baseline and Week 12 (post-intervention) | Change in visceral adipose tissue, measured in liters, will be assessed using the SECA mBCA bioelectrical impedance analysis system. | ClinicalTrials.gov |
| Secondary | Change in Handgrip Strength | Baseline and Week 12 (post-intervention) | Handgrip strength will be assessed using a calibrated hydraulic hand dynamometer. Grip force will be recorded in kilograms (kg), with higher values indicating greater muscle strength. | ClinicalTrials.gov |
| Secondary | Change in Cardiorespiratory Fitness (6-minute walk test (6MWT)) | Baseline and Week 12 (post-intervention) | Cardiorespiratory fitness is measured by the 6-Minute Walk Test (6MWT) as the total distance walked (meters) in six minutes. | ClinicalTrials.gov |
| Secondary | Change in Nutritional Intake and Diet Quality | Baseline and Week 12 (post-intervention) | Diet quality will be assessed using the Mini-EAT instrument. The Mini-EAT generates a total score ranging from 0 to 90 points, with higher scores indicating greater adherence to healthy dietary patterns and better overall diet quality. | ClinicalTrials.gov |
| Secondary | Change in Depression Symptoms | Baseline and Week 12 (post-intervention) | Depression symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 consists of 9 items with a total score ranging from 0 to 27, with higher scores indicating greater severity of depressive symptoms. | ClinicalTrials.gov |
| Secondary | Change in Anxiety Symptoms | Baseline and Week 12 (post-intervention) | Anxiety symptoms will be assessed using the Generalized Anxiety Disorder 7-item scale (GAD-7). The GAD-7 consists of 7 items with a total score ranging from 0 to 21, with higher scores indicating greater severity of anxiety symptoms. | ClinicalTrials.gov |
| Secondary | Change in General Well-Being | Baseline and Week 12 (post-intervention) | General well-being will be assessed using the World Health Organization-5 Well-Being Index (WHO-5). The WHO-5 consists of 5 items with a total raw score ranging from 0 to 25, with higher scores indicating better well-being. | ClinicalTrials.gov |
| Secondary | Change in Composite Blood Lipid Profile | Baseline and Week 12 (post-intervention) | A composite blood lipid score will be calculated using total cholesterol (mg/dL), low-density lipoprotein (LDL) cholesterol (mg/dL), high-density lipoprotein (HDL) cholesterol (mg/dL), and triglycerides (mg/dL) measurements obtained from blood samples collected and analyzed using standard clinical laboratory methods. | ClinicalTrials.gov |
| Secondary | Change in High-Sensitivity C-Reactive Protein (hs-CRP) | Baseline and Week 12 (post-intervention) | Change in high-sensitivity C-reactive protein (hs-CRP) levels, measured in milligrams per liter (mg/L), will be assessed from study blood draws and/or clinically obtained laboratory results when available and authorized. | ClinicalTrials.gov |
| Secondary | Change in N-Terminal Pro-B-Type Natriuretic Peptide | Baseline and Week 12 (post-intervention) | N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, measured in picograms per milliliter (pg/mL), will be assessed from study blood draws and/or clinically obtained laboratory results when available and authorized. | ClinicalTrials.gov |
| Secondary | Change in Glycosylated Hemoglobin (HbA1c) | Baseline and Week 12 (post-intervention) | Hemoglobin A1c (HbA1c), measured as a percentage (%), will be assessed using study blood draws and/or clinically obtained laboratory results when available and authorized. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)